A Phase III Clinical Study of Adebrelimab Combined With Concurrent Chemoradiotherapy Versus Placebo Combined With Concurrent Chemoradiotherapy for the Treatment of Locally Advanced Cervical Cancer

This study aims to evaluate the efficacy of Adebrelimab plus concurrent chemoradiotherapy compared with placebo plus concurrent chemoradiotherapy for the treatment of locally advanced cervical cancer by evaluating progression-free survival (PFS).

Trial Details

NCT ID
NCT07168200
Phase
PHASE3
Sponsor
Shanghai Shengdi Pharmaceutical Co., Ltd
Status
RECRUITING
Cancer Type
Cervical Cancer
Interventions
  • SHR-1316 Injection
  • Cisplatin Injection
  • Carboplatin Injection
  • Paclitaxel Injection
  • SHR-1316 Placebo Injection
Locations (sample)
  • Shanghai, Shanghai Municipality, China|31.22222,121.45806

Key Eligibility Criteria

  • Participate in the study voluntarily, sign the informed consent form.
  • Subjects were able to provide primary or metastatic cancer samples.
  • At least one measurable lesion.
  • Expected survival \> 3 months.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Cervical Cancer Trials on Trialify →